Perioperative Nitric Oxide Prevents Acute Kidney Injury in Acute Type A Aortic Dissection Patients
Key facts
- Who runs it
- Beijing Anzhen Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 106 people enrolled
- Started
- 30 Nov 2024
- Ended
- 2 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Nitric Oxide
- Placebo
- Record updated
- 5 February 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Provide written informed consent
- Participants must be over 18 years of age
- Participants should meet the diagnostic and treatment guidelines for thoracic aortic diseases jointly issued by ACC/AHA in 2022, have received clinical and radiological diagnosis of acute type A aortic dissection, and undergone surgical thoracotomy within two weeks after symptom onset
Who cannot take part
- Previous renal tumor, kidney transplantation, and other related surgery
- History of kidney disease, including glomerular diseases: acute glomerulonephritis, rapidly progressive glomerulonephritis, chronic glomerulonephritis, nephrotic syndrome, etc., secondary nephropathy: lupus nephritis, diabetic nephropathy, interstitial nephritis, renal tubular disease, chronic renal failure, renal replacement therapy, etc
- History of malignant tumor or received radiotherapy and chemotherapy
- Severe skeletal muscle disease and autoimmune disease
- Pregnant and lactating women, patients with mental disorders
- With intravascular or extravascular hemolytic disease
- Missing baseline value or missing postoperative serum creatinine value (Scr)
- Preoperative eGFR less than 30ml/min/1.73m2 or receive renal replacement therapy
- Patients with single kidney
- Preoperative dissection rupture or hemodynamic instability (systolic blood pressure <90mmHg)
- Life expectancy less than 90 days
- Have participated in other clinical trials
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to determine the effectiveness of exogenous nitric oxide therapy in reducing the occurrence of acute kidney injury in patients with acute type A aortic dissection. Additionally, it aims to assess the safety of exogenous nitric oxide therapy.
The 2 groups in the trial
- Nitric OxideTreatment being tested
Patients in this group receive treatment with exogenous nitric oxide (NO) via the CPB machine. After CPB, NO is administered through the inspiratory limb of the anesthetic or ventilator circuit and then via the mechanical ventilator in the ICU. Once patients are extubated, they will breathe NO through a facemask or nasal cannula. NO administration begins at the start of CPB and continues for 12 hours post-operation.
- Usual carePlacebo, for comparison
Patients in this group receive a sham treatment without the supply of nitric oxide during CPB and for 12 hours post-operation.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Nitric Oxide Administration for Reducing the Risk of Acute Kidney Injury in Patients With Acute Type A Aortic Dissection: a Randomized Controlled Trial
- Publications
- Record updated
- 5 February 2026